IL-1 blockade with anakinra for severe inflammatory symptoms during chemotherapy for acute lymphoblastic leukemia

Pediatr Blood Cancer. 2022 Mar;69(3):e29404. doi: 10.1002/pbc.29404. Epub 2021 Oct 9.

Authors

Affiliations

¹ Pediatric Hematology-Oncology, Institute for Maternal and Child Health IRCCS "Burlo Garofolo,", Trieste, Italy.
² Pediatric Hematology/Oncology Department, Meyer Children's University Hospital, Florence, Italy.
³ Department of Pediatrics, Institute for Maternal and Child Health IRCCS "Burlo Garofolo,", Trieste, Italy.
⁴ Department of Medicine, Surgery, and Health Sciences, University of Trieste, Trieste, Italy.

PMID: 34626457
DOI: 10.1002/pbc.29404

No abstract available

Publication types

Letter

MeSH terms

Acute Disease
Humans
Interleukin 1 Receptor Antagonist Protein* / therapeutic use
Interleukin-1
Precursor Cell Lymphoblastic Leukemia-Lymphoma* / drug therapy

Substances

Interleukin 1 Receptor Antagonist Protein
Interleukin-1